Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/54547

Title:	Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)
Authors:	Rubio, María Jesús Lecumberri, María José Varela, Silvia Alarcón, Jesús Ortega, María Eugenia Gaba, Lydia Espinós, Jaime calzas, julia Barretina, Pilar Ruiz, Isabel Marquina, Gloria Santaballa, Ana View more
Filiation:	Servicio de Oncología. Hospital Universitario de Fuenlabrada
Keywords:	Efficacy GEICO Metastatic Trabectedin Uterine leiomyosarcoma View more
Mesh:	Trabectedin Leiomyosarcoma Uterus View more
Decs:	Trabectedina Leiomiosarcoma Útero View more
Issue Date:	Aug-2020
Publisher:	Elsevier BV
Citation:	Rubio MJ, Lecumberri MJ, Varela S, Alarcón J, Ortega ME, Gaba L, et al. Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: a retrospective multicenter study of the Spanish ovarian cancer research group (GEICO). Gynecol Oncol Rep. 2020;33:100594.
Abstract:	We assessed trabectedin in patients with advanced uterine leiomyosarcoma (uLMS) in real-life clinical practice given according to the marketing authorization.
PMID:	32566719
URI:	https://hdl.handle.net/20.500.12530/54547
Rights:	info:eu-repo/semantics/openAccess
Appears in Collections:	Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:

File	Description	Size	Format
Gynecol Oncol Rep.pdf		420.58 kB	Adobe PDF	View/Open

This item is licensed under a Creative Commons License